Do bisphosphonates keep working after women stop taking them?

Article

Women who stop taking alendronate after 5 years do not seem to be at any greater risk for fractures than women who continue treatment, but they do seem to experience a moderate decline in bone mineral density (BMD) and a gradual rise in chemical markers associated with fractures.

Women who stop taking alendronate after 5 years do not seem to be at any greater risk for fractures than women who continue treatment, but they do seem to experience a moderate decline in bone mineral density (BMD) and a gradual rise in chemical markers associated with fractures.

The findings come from The Fracture Intervention Trial Long-term Extension (FLEX), a study of just over 1,000 postmenopausal women randomized to receive 5 mg/d or 10 mg/d alendronate or placebo for 5 years.

Compared to women who continued taking alendronate past the 5-year mark, those who quit had less BMD at the total hip (–2.4%) and spine (–3.7%), but mean levels remained at or above pretreatment levels from 10 years prior. The women who quit treatment also had 55.6% (P<0.001) higher levels of C-telopeptide of type 1 collagen, 59.5% (P<0.001) higher levels of serum N=propeptide of type 1 collagen, and 28.1% (P<0.001) higher levels of bone-specific alkaline phosphatase, but after 5 years without therapy, levels remained somewhat below pretreatment levels of 10 years earlier.

Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938.

Recent Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
© 2024 MJH Life Sciences

All rights reserved.